🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Egypt / NCT07749833
Starting soon Not applicable

EFFICACY OF ARTIFICIAL INTELLIGENCE DRIVEN PROGRAM VERSUS TRADITIONAL PHYSICAL THERAPY PROGRAM IN PATIENTS WITH LOW BACK DYSFUNCTION

NCT07749833 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-08
Last updated
2026-08-07

Condition(s) studied

Low Back PainLow Back Dysfunction

Investigational drug(s) / intervention(s)

AI-Driven Rehabilitation ProgramTraditional Physical Therapy Program

AI-Driven Rehabilitation Program: A personalized rehabilitation program guided by artificial intelligence, including individualized exercise prescription and progression.

Traditional Physical Therapy Program: A conventional physical therapy rehabilitation program delivered according to the study protocol

Study summary

Low back dysfunction is one of the most common musculoskeletal disorders and is associated with pain, disability, and reduced quality of life. Artificial intelligence (AI) has emerged as a promising tool to support personalized rehabilitation by improving exercise prescription, monitoring adherence, and providing real-time feedback. This randomized controlled trial aims to compare the effectiveness of an AI-driven rehabilitation program with a traditional physical therapy program in patients with low back dysfunction. Primary outcomes include pain intensity, functional disability, and quality of life. The findings may provide evidence regarding the role of AI-assisted rehabilitation in improving clinical outcomes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18-45 years. * Male or female participants. * Clinical diagnosis of low back dysfunction by a physiotherapist or physician. * Symptoms lasting more than 3 months. * Ability to participate in physical therapy or use AI-based rehabilitation tools. * Willingness to comply with the study protocol and provide written informed consent. Exclusion Criteria: * Recent spinal injury or spinal surgery. * Previous spinal surgery within the last 6 months. * Severe neurological disorders (e.g., multiple sclerosis or Parkinson's disease). * Chronic conditions that significantly limit mobility (e.g., advanced arthritis). * Current use of strong opioid analgesics. * Severe psychiatric disorders. * Inability to use or access the required technology for the AI intervention.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Faculty of Physical Therapy, Cairo University Cairo Cairo Governorate

More Cairo University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07749833 on ClinicalTrials.gov ↗ ← All trials in Egypt